

Virusee[®]

COVID-19 IgM/IgG Lateral Flow Assay

One drop of blood

10 minutes get the reliable result



Overview

Novel Coronavirus causes acute pneumonia and is easily transmitted person to person and person to infected objects. After emerging, patients infected by Novel Coronavirus Disease (COVID-19) have been successively discovered all over the world in a short time. At present, the global cumulative number of proved cases has reached 693,224 cases, and the global cumulative death has reached 33,106 cases, patients with COVID-19 are distributed in more than 186 countries and regions, and still increasing rapidly. Nowadays, the diagnosis method widely used in clinical is real-time PCR. However, nucleic acid detection often gives false negative results due to sampling methods, virus titers, etc.

An accurate and rapid detection is crucial in weathering the COVID-19.

Epidemiology

Source of infection: The novel coronavirus infected patients, asymptomatic

patients can also be a source of infection

Transmission: Respiratory droplets and Close contact transmission (Main),

Aerosol transmission

Susceptible population: Generally susceptible


Novel Coronavirus is more contagious than SARS-CoV and MERS-CoV

Generally Susceptible

Screening Tests are Acutely Needed

Experimental Principle

Relationship between antibody concentration and viral infection stage



Anti-COVID-19 antibody

Plasma; Serum; Whole blood

NC membrane Control line of Anti-mouse Ab


Detection line of COVID-19 specific antigen

Product Characteristics

Basic Parameters	COVID-19 lgM/lgG Lateral Flow Assay
Method	Lateral Flow Assay
Specification	20 tests/kit
Sample type	Whole blood / Serum / Plasma
Sample volume	10 μΙ
Detection time	10 min
Detection objects	Novel Coronavirus
Stability	The kit is stable for 2 years at 2°C-30°C
Sensitivity	97.33%
Specificity	99.20%

Operation Procedure

Cassette type (20 tests/kit)








Add 10µl of sample into the sample well



Add 2 drops of sample diluent into the sample well and wait for 10min



Read the result

Product Advantages

Point-Of-Care Test


- * Rapid: Obtain result within 10 min
- *Simple: Easy to use, only need one drop of blood
- * Intuitive result: There is no need for calculation and instrument, visual reading result
- **Economic:** Product can be transported and stored at room temperature, reducing costs
- **★ Low risk:** Testing blood sample, reducing the risk of sampling process

Suitable for screening on-site, bedside, outpatient

Reference

1. National Health Commission of the People's Republic of China. The diagnosis and treatment suggestion of novel coronavirus pneumonia [online].

Available at: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml [Accessed 19 February 2020]



Tel: +86(22)60978609 ext. 8603/8606/8608/8609

Fax: +86(22)60978609-804

E-mail: marketing@era-bio.com / customer@era-bio.com

Web: www.era-bio.com









Add: 2-1,2,3-101, No.2 Zone, Binlv Industrial Park, Binhai Tourism Area, Binhai New Area, Tianjin 300480, P. R. China



Add: 1601, Building C2, TEDA MSD-C, No. 79, 1st Avenue, Tianjin Economic-Technological Development Area, Tianjin 300457, P. R. China